Current Editions
How CMS’s IRA methodology will steer medicine
Choice of comparator will determine if the agency prioritizes innovation or price
Politics, Policy & Law
Data Byte
Neumora hold likely more of a setback for company than drug class
At least seven biopharmas have disclosed M4 programs for schizophrenia
Deals
Vertex’s Alpine buy, Goldman’s venture & IRA tea leaves: a BioCentury podcast
Plus: A look at BioCentury’s new R&D conference, Grand Rounds
Deals report: Vertex’s biggest deal yet, and more
Novartis gets two androgen receptor protein degraders from Arvinas and Genentech-Adaptimmune terminate allogeneic T cell therapy deal
Management Tracks
Viatris hires Corinne Le Goff as commercial head
Plus: Exact, Obsidian name new CFOs and updates from Applied, Faron, Athira and more
BioCentury ISSN 1097-7201